AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3145064 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue (0.05 U/kg)
Number of subjects: 7
Study 3145064 — intervention group
Group type: COMPARATOR
Intervention: 125I labelled soluble human insulin (0.1 U/kg)
Number of subjects: 7
Study 3145064 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogue (0.1 U/kg)
Number of subjects: 7
Study 3145064 — intervention group
Group type: COMPARATOR
Intervention: Soluble insulin (0.05 U/kg)
Number of subjects: 7
Study 3145064 — intervention group
Group type: COMPARATOR
Intervention: Soluble insulin (0.1 U/kg)
Number of subjects: 7
Study 29862411 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus plus exemestane (10 mg/d + 25 mg/d)
Number of subjects: 309
Study 29862411 — intervention group
Group type: COMPARATOR
Intervention: everolimus alone (10 mg/d)
Number of subjects: 309
Study 29862411 — intervention group
Group type: COMPARATOR
Intervention: capecitabine alone (1250 mg/m2 twice daily)
Number of subjects: 309
Study 28642554 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube video intervention
Number of subjects: 67
Study 28642554 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal and written information (Control)
Number of subjects: 67
Study 25153249 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaris stent
Number of subjects: 144
Study 25153249 — intervention group
Group type: COMPARATOR
Intervention: Percuflex stent
Number of subjects: 144
Study 23306596 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program (12 sessions)
Number of subjects: 0
Study 23306596 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program (12 sessions) under research contexts (with weekly supervision)
Number of subjects: 0
Study 23306596 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Toddler Parenting Program with London cost weighting
Number of subjects: 0
Study 20833991 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-enriched ADA diet (20% of energy from almonds, approximately 2 oz per day)
Number of subjects: 65
Study 18947487 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS-formula feeding (2.4 g/L)
Number of subjects: 371
Study 18947487 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 371
Study 18947487 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding without GOS
Number of subjects: 371
Study 15843764 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine at a dose of 4 mg/day
Number of subjects: 31
Study 12592082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene (oral or topical gel)
Number of subjects: 10
Study 10470423 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 450 mg/m2 plus Levamisol (B)
Number of subjects: 187
Study 10470423 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 600 mg/m2 (C)
Number of subjects: 187
Study 10470423 — intervention group
Group type: COMPARATOR
Intervention: Observation only (A)
Number of subjects: 187
Study 8767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg as single dose followed by 300 mg t.i.d.
Number of subjects: 80
Study 8767614 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinidine 900 mg/24 hours + digoxin if necessary
Number of subjects: 80
Study 1826073 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms sufentanil (group A)
Number of subjects: 45
Study 1826073 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine (group B)
Number of subjects: 45
Study 1826073 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms sufentanil plus 3 mg morphine (group C)
Number of subjects: 45
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 30
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg)
Number of subjects: 30
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (30 mg)
Number of subjects: 30
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (300 mg)
Number of subjects: 30
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulations of analgesic combinations (aminophenazone replaced by propyphenazone)
Number of subjects: 30
Study 6991534 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg)
Number of subjects: 30
Study 6991534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6991534 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (1000 mg) vs Placebo
Number of subjects: 30
Study 28222149 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment (20, 40, and 60 mg/kg)
Number of subjects: 283
Study 28222149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 25887550 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (MMT) including neurophysiological education, sensory training, and motor training, with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Number of subjects: 28
Study 25887550 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy treatment (UPT), with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Number of subjects: 28
Study 25887550 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (MMT)
Number of subjects: 28
Study 25887550 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy treatment (UPT)
Number of subjects: 28
Study 24014982 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive multifocal IOL
Number of subjects: 25
Study 24014982 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-accommodative IOL
Number of subjects: 25
Study 21382958 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarity Therapy (PT)
Number of subjects: 45
Study 21382958 — intervention group
Group type: COMPARATOR
Intervention: Modified Massage
Number of subjects: 45
Study 21382958 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 45
Study 19636365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days
Number of subjects: 80
Study 19636365 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent antimony plus placebo (vehicle cream) applied as above
Number of subjects: 80
Study 16454145 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate nasal spray (10 mmol)
Number of subjects: 77
Study 16454145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 15281969 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 29
Study 15281969 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 29
Study 11410114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg for 8 weeks
Number of subjects: 23
Study 9241569 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0
Study 9241569 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 7686216 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks (PV)
Number of subjects: 218
Study 7686216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks with Bleomycin 30 mg IM weekly (PVB)
Number of subjects: 218
Study 7686216 — intervention group
Group type: COMPARATOR
Intervention: PV
Number of subjects: 218
Study 7686216 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 218
Study 3575424 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch and ultrasound (SS and US)
Number of subjects: 30
Study 3575424 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch (SS)
Number of subjects: 30
Study 3575424 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 29356899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training program (MAP)
Number of subjects: 81
Study 29356899 — intervention group
Group type: COMPARATOR
Intervention: Structured psychoeducation (PE)
Number of subjects: 81
Study 26630538 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-impregnated intrauterine system (LNG‐IUS)
Number of subjects: 153
Study 26630538 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral medroxyprogesterone acetate (MPA) administered for 10 days per cycle for 6 months
Number of subjects: 153
Study 26630538 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral medroxyprogesterone acetate (MPA) administered daily for 6 months
Number of subjects: 153
Study 24152323 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system with predictive rule-based algorithm (pRBA)
Number of subjects: 10
Study 24152323 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) system
Number of subjects: 10
Study 22134043 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 224
Study 22134043 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2.5‐10 mg/day)
Number of subjects: 224
Study 22134043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 20507374 — intervention group
Group type: EXPERIMENTAL
Intervention: New dentifrice containing zinc‐carbonate hydroxyapatite (CHA) nanocrystals
Number of subjects: 70
Study 20507374 — intervention group
Group type: COMPARATOR
Intervention: Potassium nitrate/fluoride dentifrice (active control)
Number of subjects: 70
Study 20507374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dentifrices
Number of subjects: 70
Study 16708310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests (CRP, leucocyte count, rapid Strep A, chest X-ray, sinus X-ray, throat culture)
Number of subjects: 1108
Study 16708310 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP test (above 50 mg/l)
Number of subjects: 1108
Study 16708310 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte count (above 10,000/microl)
Number of subjects: 1108
Study 16708310 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Strep A test
Number of subjects: 1108
Study 16708310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests
Number of subjects: 1108
Study 11356731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin + diet (ND)
Number of subjects: 116
Study 11356731 — intervention group
Group type: COMPARATOR
Intervention: Placebo + diet (PD)
Number of subjects: 116
Study 11356731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (N)
Number of subjects: 116
Study 11356731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 116
Study 9135240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single latex gloves
Number of subjects: 25
Study 9135240 — intervention group
Group type: EXPERIMENTAL
Intervention: Double latex gloves
Number of subjects: 25
Study 9135240 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Kevlar glove with latex inside and outside
Number of subjects: 25
Study 9135240 — intervention group
Group type: EXPERIMENTAL
Intervention: Kevlar and Medak glove with latex inside and outside
Number of subjects: 25
Study 9135240 — intervention group
Group type: COMPARATOR
Intervention: No gloves
Number of subjects: 25
Study 7525692 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG anti‐HCVcore
Number of subjects: 71
Study 7525692 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM anti‐HCVcore
Number of subjects: 71
Study 7525692 — intervention group
Group type: EXPERIMENTAL
Intervention: Viremic levels
Number of subjects: 71
Study 7525692 — intervention group
Group type: COMPARATOR
Intervention: Correlation of IgM anti‐HCVcore
Number of subjects: 71
Study 3654485 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of teacher intrusion
Number of subjects: 0
Study 3654485 — intervention group
Group type: COMPARATOR
Intervention: Low level of teacher intrusion
Number of subjects: 0
Study 29804268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 149
Study 29804268 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 149
Study 27448051 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 380
Study 27448051 — intervention group
Group type: COMPARATOR
Intervention: High-definition white light (HDWL)
Number of subjects: 380
Study 25522395 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 15
Study 22808045 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated blood transfusion/fluid infusion
Number of subjects: 160
Study 22808045 — intervention group
Group type: EXPERIMENTAL
Intervention: Body wrapping and heating blanket
Number of subjects: 160
Study 22808045 — intervention group
Group type: EXPERIMENTAL
Intervention: Body wrapping, heated moist dressings, and heating blanket
Number of subjects: 160
Study 22808045 — intervention group
Group type: EXPERIMENTAL
Intervention: Body wrapping, heated moist dressings, and warmed surgical rinse fluid
Number of subjects: 160
Study 22808045 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving warming methods)
Number of subjects: 160
Study 20479297 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept, 50 mg, SC administered twice weekly for 12 weeks
Number of subjects: 20
Study 20479297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18184958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 537
Study 18184958 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 537
Study 18184958 — intervention group
Group type: EXPERIMENTAL
Intervention: HES therapy
Number of subjects: 537
Study 18184958 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 537
Study 15844469 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA replacement (50 mg/day)
Number of subjects: 5
Study 15844469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15318461 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 54
Study 15318461 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose remifentanil (1 microg kg(‐1))
Number of subjects: 54
Study 15318461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (3 microg kg(‐1))
Number of subjects: 54
Study 15318461 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (any dose)
Number of subjects: 54
Study 11386092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 28
Study 11386092 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% plus 0.5 microgram ml‐1 sufentanil
Number of subjects: 28
Study 9225534 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 500ppm NaF plus 500ppm NaMFP
Number of subjects: 1633
Study 9225534 — intervention group
Group type: COMPARATOR
Intervention: Control product containing 1000ppm NaMFP
Number of subjects: 1633
Study 8128328 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic thrombin injections in actively bleeding patients (group II, N = 94)
Number of subjects: 191
Study 8128328 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic thrombin injections in non-bleeding visible vessels (group A, N = 25)
Number of subjects: 191
Study 8128328 — intervention group
Group type: COMPARATOR
Intervention: Conventional management in actively bleeding patients (group I, N = 47)
Number of subjects: 191
Study 8128328 — intervention group
Group type: COMPARATOR
Intervention: No primary endoscopic treatment in non-bleeding visible vessels (group B, N = 25)
Number of subjects: 191
Study 3325472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pili canaliculi hair abnormality
Number of subjects: 0
Study 30593081 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated Birth Score (score range 0 to 86)
Number of subjects: 121640
Study 30593081 — intervention group
Group type: COMPARATOR
Intervention: Current Birth Score
Number of subjects: 121640
Study 29472134 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tDCS (7-min)
Number of subjects: 75
Study 29472134 — intervention group
Group type: EXPERIMENTAL
Intervention: Double tDCS (7-min and 5-min separated by 3-min rest)
Number of subjects: 75
Study 26731401 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive short message services (SMS) sent to HSAs during a 12-month period, including motivational and data quality SMS.
Number of subjects: 0
Study 26731401 — intervention group
Group type: COMPARATOR
Intervention: Motivational SMS only (control group).
Number of subjects: 0
Study 26731401 — intervention group
Group type: COMPARATOR
Intervention: Comparison between treatment and control groups during the intervention period.
Number of subjects: 0
Study 25049135 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% whey protein isolate drink (528 kJ) (PRO)
Number of subjects: 12
Study 25049135 — intervention group
Group type: COMPARATOR
Intervention: low energy placebo (15 kJ) (PLA)
Number of subjects: 12
Study 25049135 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sucrose drink (528 kJ) (CHO)
Number of subjects: 12
Study 22664664 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative ISA
Number of subjects: 153
Study 22664664 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive ISA
Number of subjects: 153
Study 22664664 — intervention group
Group type: COMPARATOR
Intervention: ISA turned off
Number of subjects: 153
Study 22664664 — intervention group
Group type: EXPERIMENTAL
Intervention: PAYS concept
Number of subjects: 153
Study 22664664 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA on rural roads
Number of subjects: 153
Study 22664664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean free flow speed and 85th percentile speed
Number of subjects: 153
Study 20346780 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 561
Study 20346780 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.0125%
Number of subjects: 561
Study 20346780 — intervention group
Group type: COMPARATOR
Intervention: bimatoprost 0.03%
Number of subjects: 561
Study 17654740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patients with PBC
Number of subjects: 535
Study 17654740 — intervention group
Group type: COMPARATOR
Intervention: Non-Caucasian patients with PBC
Number of subjects: 535
Study 17654740 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Caucasian patients (African American and Hispanic)
Number of subjects: 535
Study 17654740 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian and Non-Caucasian patients
Number of subjects: 535
Study 15804195 — intervention group
Group type: EXPERIMENTAL
Intervention: Abuse-prevention curriculum designed to empower women with mental retardation
Number of subjects: 36
Study 15804195 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 15804195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 36
Study 12572380 — intervention group
Group type: EXPERIMENTAL
Intervention: Qinghuo Baidu Yin (QHBDY)
Number of subjects: 30
Study 12572380 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + QHBDY
Number of subjects: 30
Study 12572380 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 9794854 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for cost data
Number of subjects: 45
Study 9794854 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic evaluations
Number of subjects: 45
Study 8556909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 150 mg single dose treatment
Number of subjects: 24
Study 8556909 — intervention group
Group type: COMPARATOR
Intervention: Early pregnant cervix before treatment
Number of subjects: 24
Study 2242521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28
Study 2242521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-ISDN combination
Number of subjects: 28
Study 2242521 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 28
Study 577428 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyrone compound Venalot (2 depot tablets b.d.)
Number of subjects: 0
Study 29733117 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + active phototherapy (nine‐diode cluster device: one 905 nm super‐pulsed diode laser, four 875 nm LED and four 640 nm LED; energy per quadrant: 7.85 J; total energy: 23.55 J per session)
Number of subjects: 60
Study 29733117 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + active phototherapy
Number of subjects: 60
Study 29733117 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 60
Study 29733117 — intervention group
Group type: COMPARATOR
Intervention: Exercise + placebo phototherapy
Number of subjects: 60
Study 27314841 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS Expert® (paclitaxel)
Number of subjects: 34
Study 27314841 — intervention group
Group type: COMPARATOR
Intervention: BiOSS LIM® (sirolimus)
Number of subjects: 34
Study 27314841 — intervention group
Group type: EXPERIMENTAL
Intervention: Final kissing balloon/proximal optimization technique (FKB/POT)
Number of subjects: 34
Study 25012399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention delivered via the internet over a period of 52 weeks
Number of subjects: 532
Study 25012399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) intervention
Number of subjects: 532
Study 25012399 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 532
Study 22268971 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 44
Study 22268971 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration plus localized radiofrequency (WBV+RF)
Number of subjects: 44
Study 20563469 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 37
Study 20563469 — intervention group
Group type: COMPARATOR
Intervention: Control (no MUF)
Number of subjects: 37
Study 19014751 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg/day)
Number of subjects: 521